Previous 10 | Next 10 |
ADC Therapeutics SA (ADCT) Q3 2021 Earnings Conference Call November 02, 2021, 08:30 AM ET Company Participants Amanda Hamilton - Investor Relations Manager Christopher Martin - Co-Founder, CEO Jennifer Herron - Chief Commercial Officer & SVP Jennifer Creel - Chief Financial Officer Joe C...
ADC Therapeutics (NYSE:ADCT): Q3 GAAP EPS of -$0.93 misses by $0.01. Revenue of $13.15M beats by $5.76M. Press Release For further details see: ADC Therapeutics EPS misses by $0.01, beats on revenue
ZYNLONTA ® (loncastuximab tesirine-lpyl) third quarter 2021 net sales of $13.1 million Financing agreement with HealthCare Royalty for up to $325 million Company to host conference call today at 8:30 a.m. EDT ADC Therapeutics SA (NYSE: ADCT), a comme...
ADC Therapeutics (NYSE:ADCT) announces that its Marketing Authorization Application (MAA) for Zynlonta, a CD19-targeted ADC for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL), has been validated by the EMA. Validation of the application enables the evaluation pr...
Application supported by data from pivotal LOTIS-2 trial in adult patients with relapsed or refractory diffuse large B-cell lymphoma Milestone achieved in commitment to make ZYNLONTA widely available to patients in need ADC Therapeutics SA (NYSE: ADCT), a commercial-...
ADC Therapeutics SA (NYSE: ADCT), a commercial-stage biotechnology company improving the lives of those affected by cancer with its next-generation, targeted antibody drug conjugates (ADCs) for patients with hematologic malignancies and solid tumors, today announced that it will host a ...
Baker Brothers’ 13F portfolio value decreased from $23.07B to $22.77B this quarter. The InVitae stake was reduced this quarter while increasing Apellis Pharma and Heron Therapeutics. The top three positions are Seagen, BeiGene, and Incyte Corporation and they add up to almo...
The following slide deck was published by ADC Therapeutics SA in conjunction with this event. For further details see: ADC Therapeutics (ADCT) Investor Presentation
Overland ADCT BioPharma, a joint venture created by Overland Pharmaceuticals and ADC Therapeutics SA (NYSE: ADCT), today announced the first patient has been dosed with ZYNLONTA® in a pivotal Phase 2 clinical trial in patients with relapsed or refractory (r/r) diffuse large B-c...
ADCT-901 targets KAAG1, a novel tumor target for ADC development ADC Therapeutics SA (NYSE: ADCT), a commercial-stage biotechnology company improving the lives of those affected by cancer with its next-generation, targeted antibody drug conjugates (ADCs) for patients with he...
News, Short Squeeze, Breakout and More Instantly...
£90m ($114m) series A co-led by new leading life science investors Novo Holdings and Abingworth Additional new investors British Patient Capital, Cancer Research Horizons and Lilly participated alongside founding investors Brandon Capital and Sofinnova Partners Funds will be used to ...
LAUSANNE, Switzerland, June 27, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today announced that the Company is set to join the Russell 2000 ® Index and the broad-market Russell 3000 ® Index at the conclusion of the 2024 Russell US Indexes annual reconstitution, ef...